Skip to content
Open access

Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification.

Sep 2026 · Kidney Research and Clinical Practice · Vol 45, pp. 896-911 · 0 citations · 74 references
Medicine

TL;DR

Mechanical insights from translational studies further suggest that GLP-1 receptor activation promotes metabolic decongestion, improves intrarenal hemodynamics, and attenuates inflammatory and fibrotic pathways, with emerging signals for cardiovascular and renal benefit.

Abstract

Obesity and type 2 diabetes (T2D) are dominant drivers of chronic kidney disease (CKD) within the cardio-kidney-metabolic (CKM) syndrome. Despite advances with renin-angiotensin system inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors, substantial residual cardiovascular and renal risk persists, highlighting the need for therapies targeting upstream metabolic dysfunction. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as key modulators of CKM disease through integrated metabolic, vascular, and anti-inflammatory mechanisms. Cardiovascular outcome trials first established their cardioprotective effects, while the FLOW trial definitively demonstrated kidney protection, showing a 24% reduction in major kidney outcomes in patients with T2D and CKD. Mechanistic insights from translational studies further suggest that GLP-1 receptor activation promotes metabolic decongestion, improves intrarenal hemodynamics, and attenuates inflammatory and fibrotic pathways. Beyond selective GLP-1 receptor agonism, dual (glucose-dependent insulinotropic polypeptide [GIP]/GLP-1) and triple (GIP/GLP-1/glucagon) incretin agonists, including tirzepatide and retatrutide, extend this paradigm by delivering greater weight reduction and systemic metabolic reprogramming, with emerging signals for cardiovascular and renal benefit. Contemporary CKD management is shifting toward a phenotype-driven, layered therapeutic strategy in which SGLT2 inhibitors provide foundational kidney protection and incretin-based therapies are integrated to address residual metabolic and cardiovascular risk. In this evolving CKM framework, incretin-based therapies represent a central component of multi-mechanistic disease modification, extending beyond glycemic control to coordinated protection across the heart, kidney, and metabolic systems.

Read PDF

Similar papers

Review Open access Oct 2026

GLP-1 receptor agonists—a potential therapy for chronic kidney disease?

Abstract Chronic kidney disease (CKD) represents a significant health burden worldwide, characterized by a gradual decline in kidney function and increased risk of cardiovascular events. Current therapeutic strategies like inhibition of the renin-angiotensin-aldosterone system or sodium-glucose cotransporter 2 inhibito...

Jan Boeckhaus, J. Sayer, Holly R. Mabillard · 0 citations
Review Open access Aug 2026

Type 2 diabetes and the cardio–renal–metabolic syndrome: The evolving roles of GLP-1 and dual GLP-1/GIP receptor agonists

The impact of type 2 diabetes (T2D) extends beyond mere management of blood glucose; it also encompasses related cardiovascular, renal and metabolic issues. This interconnected framework, known as the cardio-renal-metabolic (CRM) syndrome, calls for a shift in therapeutic approach. While traditional treatments have mad...

Clipper F. Young, Namrita George, Alexander Olson et al. · 0 citations
Review Open access Sep 2026

Diabetic kidney disease within the framework of cardio-kidney-metabolic health: a paradigm shift

A phenotype-driven framework for sequencing combination therapy based on each patient’s dominant pathophysiologic driver as a hypothesis-generating alternative to uniform add-on strategies is proposed and the future direction of DKD management and the need for integrated multidisciplinary approaches aimed at improving...

Juarez R. Braga, F. Ayub, S. Vallurupalli et al. · 0 citations
Review Open access Oct 2026

Combination Kidney-Protective Therapy in Diabetic Kidney Disease: From RAAS Blockade to Multidrug Precision Nephrology

This review summarizes current and emerging evidence supporting combination kidney-protective therapy in DKD, including RAAS inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, finerenone, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), endothelin receptor antagonists, and aldosterone synthase inhibit...

B. Satirapoj · 0 citations
Review Open access Oct 2026

Mechanism-based therapeutic strategies in cardiovascular-kidney-metabolic syndrome: integrating biological pathways with evidence from clinical trials

Cardiovascular-kidney-metabolic (CKM) syndrome describes the close relationship between metabolic dysfunction, chronic kidney disease, and cardiovascular disease, which share several biological pathways and frequently progress together. This review examines the mechanisms and clinical trial evidence supporting establis...

John Nzobokela, Simweene C. Choolwe, S. Masenga · 0 citations
Review Open access Oct 2026

Cardiovascular–kidney–metabolic syndrome: novel molecular mechanism and glucagon-like peptide-1-targeting therapy

Cardiovascular–kidney–metabolic (CKM) syndrome represents a systemic disease continuum arising from the progressive and reciprocal interactions among metabolic dysfunction, kidney injury, and cardiovascular disease. Obesity and type 2 diabetes mellitus (T2DM) are major metabolic drivers of early CKM progression and con...

Feng-Zhao Liu, Zi-Han Xu, Wen-Ru Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.